Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...